Genmab halts enrollment for cancer drug from ProfoundBio buyout
Genmab暂停为收购普方生物所获抗癌药招募临床受试者

Genmab has stopped enrolling patients for an early-stage trial of a cancer candidate it obtained in its $1.8 billion acquisition of US-China biotech ProfoundBio.
Genmab已停止为其以18亿美元收购美中生物技术公司普方生物所获得的一款癌症候选药进行的早期临床试验招募患者。